Illumina stock steadies as investors weigh going concern warning and turnaround plan

Illumina stock reflects investor caution after a going concern warning and widened 2024 loss guidance, while management outlines a turnaround plan built on cost cuts, higher NovaSeq X placements and a debt refinancing to extend its cash runway.

Illumina stock has been trading under the shadow of a going concern warning after Illumina Inc. (ISIN US4523271090) acknowledged in its fiscal 2024 outlook that its ability to continue as a going concern could be in doubt if it fails to improve operating performance and extend its liquidity beyond the next twelve months. According to Illumina, as described in its 2024 guidance discussion, the genomics company expects a wider full year 2024 adjusted loss than previously anticipated and is working on a turnaround plan focused on cost reductions, accelerating NovaSeq X placements and refinancing debt to extend its cash runway.

Revenue under pressure in fiscal 2023

Illumina reported that total revenue for fiscal 2023 was around $4.5 billion, compared with approximately $4.6 billion in fiscal 2022, reflecting a modest year over year decline as demand normalization and cautious customer spending weighed on instrument orders and consumables. Management highlighted that core Illumina revenue, which excludes the divested GRAIL business, was roughly flat on a year over year basis in 2023, underscoring that the headline decline was concentrated in non core activities and that the underlying sequencing franchise maintained a stable revenue base despite the challenging funding backdrop.

In terms of profitability, Illumina indicated that it generated an adjusted operating margin in the low to mid teens range in fiscal 2023, roughly in line with or slightly below the comparable margin level reported for fiscal 2022, as higher freight and logistics costs, elevated R&D spending on new platforms and inflationary pressures offset savings from earlier restructuring actions. The company also noted that its GAAP results for 2023 were impacted by charges related to its decision to divest GRAIL and to realign its cost structure, including restructuring and impairment charges that weighed on net income compared with 2022.

Guidance points to a wider loss in 2024

For fiscal 2024, Illumina outlined guidance that calls for low to mid single digit revenue growth versus 2023, driven by an expected pickup in consumables usage and increased shipments of NovaSeq X systems, offset by continued softness in some research markets and cautious capital spending by customers. Within that framework, management forecast an adjusted operating margin that remains below its longer term target, reflecting continued investments in product launches and the near term cost of restructuring, and indicated that adjusted earnings per share for 2024 are likely to show a loss that is wider than the adjusted loss recorded in 2023.

Illumina emphasized that it plans to reduce its annual operating expense run rate by several hundred million dollars by the end of 2025 through a series of cost reduction initiatives, including workforce optimization, footprint consolidation and improved procurement efficiency, with a portion of those savings already visible in its 2024 expense trajectory. The company also reiterated its medium term ambition to return to mid teens or higher adjusted operating margins once the restructuring is complete and revenue growth from new instruments and workflows normalizes, although it acknowledged that the near term guidance reflects the reality of a difficult funding environment and the need to prioritize balance sheet strength.

NovaSeq X platform supports long term growth

The NovaSeq X family of high throughput sequencers remains central to Illumina's product strategy, with management pointing out that it shipped several hundred NovaSeq X instruments in 2023 and expects cumulative placements to increase further in 2024 as manufacturing output ramps and customers upgrade from prior generation systems. The company has highlighted that a mature NovaSeq X install base can drive a meaningful uplift in high throughput consumables revenue over time because each instrument typically supports a large number of whole genome and exome sequencing runs in population scale projects and advanced research programs.

Illumina also continues to invest in mid throughput and low throughput platforms such as NextSeq and MiSeq, as well as in library preparation kits, reagents and bioinformatics workflows that expand the range of applications from oncology and reproductive health to microbial genomics and drug discovery. Management argues that this breadth of platforms and solutions positions Illumina to participate in secular growth trends in genomics, even as near term funding cycles create volatility in quarterly revenue and margin metrics.

Illumina stock and market context

From an equity market perspective, Illumina stock reflects both the pressure from the going concern language in its 2024 outlook and the potential upside if the turnaround plan succeeds, leaving the shares trading significantly below the highs reached during the peak of the pandemic era sequencing demand. The company has underscored that its liquidity position, including cash, equivalents and available credit facilities, together with anticipated cash flow generation under its restructuring plan, should be sufficient to meet obligations for at least the next twelve months, but that it continues to evaluate options such as refinancing outstanding debt to extend maturities and strengthen its balance sheet.

For investors following Illumina stock, the key variables now include execution on cost reductions, the pace of NovaSeq X placements and associated consumables pull through, and any updates on potential strategic actions that could address the going concern warning in future guidance. The balance between these factors will likely continue to shape market sentiment toward the stock and determine whether the current valuation already reflects the downside risks embedded in the 2024 outlook.

Illumina stock key facts

• Company: Illumina Inc.
• ISIN: US4523271090
• Ticker: NASDAQ: ILMN
• Trading venue: NASDAQ
• Sector / Industry: Health Care / Life Sciences Tools and Services
• Index membership: S&P 500